3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase NA
2
Phase EARLY_PHASE1
2
Phase 3
2
Phase 1/2
2
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
8
NET
1
Endocrine
1
Conditions
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Interventions
Everolimus
15
Magnetic Resonance Spectroscopy
8
lutetium Lu 177 dotatate
7
pasireotide
5
gallium Ga 68 dotatate
5
Cisplatin
5
Specimen Handling
4
Positron Emission Tomography Computed Tomography
4
Nivolumab
4
Fluorodeoxyglucose F18
4
Carboplatin
4
Temozolomide
3
Paclitaxel
3
Octreotide
3
Lutetium-177
3
Ga(III)-DOTATOC
3
Etoposide
3
(177)Lu-DOTA-EB-TATE
3
vandetanib
2
pembrolizumab
2
olaparib
2
fluorodopa F 18
2
dabrafenib
2
copper dotatate CU-64
2
cemiplimab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Trastuzumab
2
Radiotherapy
2
Radiosurgery
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
3-Iodobenzylguanidine
×
Endocrine
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn